A non-invasive approach to monitor chronic lymphocytic leukemia engraftment in a xenograft mouse model using ultra-small superparamagnetic iron oxide-magnetic resonance imaging (USPIO-MRI)

Bibliographische Detailangaben
Veröffentlicht in:	Clinical immunology (Orlando, Fla.). - 1999. - 172(2016) vom: 19. Nov., Seite 52-60
1. Verfasser:	Valdora, Francesca (VerfasserIn)
Weitere Verfasser:	Cutrona, Giovanna, Matis, Serena, Morabito, Fortunato, Massucco, Carlotta, Emionite, Laura, Boccardo, Simona, Basso, Luca, Recchia, Anna Grazia, Salvi, Sandra, Rosa, Francesca, Gentile, Massimo, Ravina, Marco, Pace, Daniele, Castronovo, Angela, Cilli, Michele, Truini, Mauro, Calabrese, Massimo, Neri, Antonino, Neumaier, Carlo Emanuele, Fais, Franco, Baio, Gabriella, Ferrarini, Manlio
Format:	Online-Aufsatz
Sprache:	English
Veröffentlicht:	2016
Zugriff auf das übergeordnete Werk:	Clinical immunology (Orlando, Fla.)
Schlagworte:	Journal Article Chronic lymphocytic leukemia (CLL) Disease monitoring Magnetic resonance imaging (MRI) Ultra-small superparamagnetic iron oxide (USPIO) Xenograft NSG mice model Antineoplastic Agents Ferric Compounds ferric oxide 1K09F3G675 mehr... Rituximab 4F4X42SYQ6


LEADER	01000naa a22002652 4500
001	NLM262546949
003	DE-627
005	20231224202006.0
007	cr uuu---uuuuu
008	231224s2016 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1016/j.clim.2016.07.013 \|2 doi
028	5	2	\|a pubmed24n0875.xml
035			\|a (DE-627)NLM262546949
035			\|a (NLM)27430522
035			\|a (PII)S1521-6616(16)30176-0
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
100	1		\|a Valdora, Francesca \|e verfasserin \|4 aut
245	1	2	\|a A non-invasive approach to monitor chronic lymphocytic leukemia engraftment in a xenograft mouse model using ultra-small superparamagnetic iron oxide-magnetic resonance imaging (USPIO-MRI)
264		1	\|c 2016
336			\|a Text \|b txt \|2 rdacontent
337			\|a ƒaComputermedien \|b c \|2 rdamedia
338			\|a ƒa Online-Ressource \|b cr \|2 rdacarrier
500			\|a Date Completed 12.05.2017
500			\|a Date Revised 12.05.2017
500			\|a published: Print-Electronic
500			\|a Citation Status MEDLINE
520			\|a Copyright © 2016 Elsevier Inc. All rights reserved.
520			\|a Chronic lymphocytic leukemia (CLL) is the most prevalent leukemia among adults. Despite its indolent nature, CLL remains an incurable disease. Herein we aimed to monitor CLL disease engraftment and, progression/regression in a xenograft CLL mouse model using ultra-small superparamagnetic iron oxide-magnetic resonance imaging (USPIO-MRI). Spleen contrast enhancement, quantified as percentage change in signal intensity upon USPIO administration, demonstrated a difference due to a reduced USPIO uptake, in the spleens of mice injected with CLL cells (NSG-CLL, n=71) compared to controls (NSG-CTR, n=17). These differences were statistically significant both after 2 and 4weeks from CLL cells injection. In addition comparison of mice treated with rituximab with untreated controls for changes in spleen iron uptake confirmed that it is possible to monitor treatment efficacy in this mouse model of CLL using USPIO-enhanced MRI. Further applications could include the preclinical in vivo monitoring of new therapies and the clinical evaluation of CLL patients
650		4	\|a Journal Article
650		4	\|a Chronic lymphocytic leukemia (CLL)
650		4	\|a Disease monitoring
650		4	\|a Magnetic resonance imaging (MRI)
650		4	\|a Ultra-small superparamagnetic iron oxide (USPIO)
650		4	\|a Xenograft NSG mice model
650		7	\|a Antineoplastic Agents \|2 NLM
650		7	\|a Ferric Compounds \|2 NLM
650		7	\|a ferric oxide \|2 NLM
650		7	\|a 1K09F3G675 \|2 NLM
650		7	\|a Rituximab \|2 NLM
650		7	\|a 4F4X42SYQ6 \|2 NLM
700	1		\|a Cutrona, Giovanna \|e verfasserin \|4 aut
700	1		\|a Matis, Serena \|e verfasserin \|4 aut
700	1		\|a Morabito, Fortunato \|e verfasserin \|4 aut
700	1		\|a Massucco, Carlotta \|e verfasserin \|4 aut
700	1		\|a Emionite, Laura \|e verfasserin \|4 aut
700	1		\|a Boccardo, Simona \|e verfasserin \|4 aut
700	1		\|a Basso, Luca \|e verfasserin \|4 aut
700	1		\|a Recchia, Anna Grazia \|e verfasserin \|4 aut
700	1		\|a Salvi, Sandra \|e verfasserin \|4 aut
700	1		\|a Rosa, Francesca \|e verfasserin \|4 aut
700	1		\|a Gentile, Massimo \|e verfasserin \|4 aut
700	1		\|a Ravina, Marco \|e verfasserin \|4 aut
700	1		\|a Pace, Daniele \|e verfasserin \|4 aut
700	1		\|a Castronovo, Angela \|e verfasserin \|4 aut
700	1		\|a Cilli, Michele \|e verfasserin \|4 aut
700	1		\|a Truini, Mauro \|e verfasserin \|4 aut
700	1		\|a Calabrese, Massimo \|e verfasserin \|4 aut
700	1		\|a Neri, Antonino \|e verfasserin \|4 aut
700	1		\|a Neumaier, Carlo Emanuele \|e verfasserin \|4 aut
700	1		\|a Fais, Franco \|e verfasserin \|4 aut
700	1		\|a Baio, Gabriella \|e verfasserin \|4 aut
700	1		\|a Ferrarini, Manlio \|e verfasserin \|4 aut
773	0	8	\|i Enthalten in \|t Clinical immunology (Orlando, Fla.) \|d 1999 \|g 172(2016) vom: 19. Nov., Seite 52-60 \|w (DE-627)NLM098196855 \|x 1521-7035 \|7 nnns
773	1	8	\|g volume:172 \|g year:2016 \|g day:19 \|g month:11 \|g pages:52-60
856	4	0	\|u http://dx.doi.org/10.1016/j.clim.2016.07.013 \|3 Volltext
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_NLM
912			\|a GBV_ILN_11
912			\|a GBV_ILN_24
912			\|a GBV_ILN_350
951			\|a AR
952			\|d 172 \|j 2016 \|b 19 \|c 11 \|h 52-60